Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05347394 | A Phase 1 Dose Escalation Study of Oral VX-708 in Healthy Participants | PHASE1 | COMPLETED | 100 | — | — | Apr 8, 2022 | Apr 14, 2023 | May 15, 2023 | 1 | United Kingdom |
| Arm | Type | Description |
|---|---|---|
| Part A: VX-708 | EXPERIMENTAL | Participants will be randomized to receive a single dose of different dose levels of VX-708. |
| Part A: Placebo | PLACEBO_COMPARATOR | Participants will receive placebo matched to VX-708. |
| Part B: VX-708 | EXPERIMENTAL | Participants will be randomized to receive multiple doses of different dose levels of VX-708. The dose levels will be determined based on the data from Part A. |
| Part B: Placebo | PLACEBO_COMPARATOR | Participants will receive placebo matched to VX-708. |
| Name | Type | Description |
|---|---|---|
| VX-708 | DRUG | Solution or suspension for oral administration. |
| Placebo | DRUG | Placebo matched to VX-708 for oral administration. |
Key Inclusion Criteria: * Male and female of non-childbearing potential are eligible * Body mass index (BMI) of 18.0 to 32.0 kilograms per meter square (kg/m\^2) * A total body weight greater than (\>) 50 kg Key Exclusion Criteria: * History of febrile illness or other acute illness within 14 day...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Fresenius Medical Care AG Sponsored ADR | FMS | 2 | PHASE3 | Dialysis |
| AstraZeneca PLC | AZN | 1 | PHASE2 | AZD4144 |
| CalciMedica, Inc. | CALC | 1 | PHASE2 | Auxora |
| Talphera, Inc. | TLPH | 1 | NA | Undisclosed |
| SeaStar Medical Holding Corporation | ICU | 2 | — | Undisclosed |
| Collegium Pharmaceutical, Inc. | COLL | 1 | — | Flozin |